Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
12 March 2024 - 11:00PM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
biotechnology company developing first-in-classi targeted and
immune-mediated therapeutics to fight cancer, today announced a
poster presentation at the Society for Immunotherapy of Cancer
(SITC) 2024 Spring Scientific Meeting highlighting preclinical data
showing potent anti-tumor activity in several cancer models treated
with TPST-1120 alone or with immune checkpoint inhibitors. The
presentation covered experimental results that corroborated
clinical biomarker data from patients with advanced solid tumor
cancers treated in a Phase 1 trial with TPST-1120 showing increased
expression of select immune-related genes and elevated plasma Free
Fatty Acid (FFA) levels associated with clinical response.
TPST-1120 is an oral, selective PPAR⍺ antagonist in clinical
development that has shown promising results, including positive
data from a randomized study in first-line hepatocellular carcinoma
(HCC) patients compared to the standard of care.
“Data presented at the SITC Spring Scientific
Meeting bolster our mechanistic understanding of
PPARα blockade in cancer patients and reinforce a basis for
the ongoing late-stage clinical development of TPST-1120,” said Sam
Whiting, M.D., Ph.D., chief medical officer and head of R&D at
Tempest. “Based on positive Phase 1 and 2 data, we are planning a
pivotal study in patients with first-line liver cancer, and we also
look forward to evaluating the potential of TPST-1120 in additional
cancer indications.”
In preclinical models of liver, colon and
pancreatic cancer, TPST-1120 elicited a greater than 50% inhibition
of tumor growth with enhanced inhibition observed in liver and
colon cancer models when co-administered with anti-PD-1. In
addition, biomarker results from the Phase 1 clinical trial of
TPST-1120 in multiple solid tumor indications showed statistically
significant, exposure-dependent elevations in expression levels of
multiple immune-related genes, and patients exhibiting objective
responses displayed increased circulating free fatty acids (FFA),
both of which are in-line with the proposed TPST-1120 mechanism of
action. Clinical response and biomarker findings support that
inhibition of PPARα may be an effective therapeutic strategy
for the treatment of cancer.
These findings complement positive data reported
in October 2023 from a global randomized phase 1b/2 study of
TPST-1120 in combination with atezolizumab and bevacizumab in
first-line patients with advanced HCC. The differentiating data
showed clinical superiority of the TPST-1120 arm across multiple
study endpoints and relevant biomarker-defined patient
subpopulations when compared to atezolizumab and bevacizumab alone,
the standard of care in first-line HCC.
About TPST-1120
TPST-1120 is an oral, small molecule, selective
PPAR⍺ antagonist. Tempest’s data suggest that TPST-1120 treats
cancer by targeting tumor cell metabolism directly, as well as by
modulating immune suppressive cells and angiogenesis in the tumor
microenvironment. In a Phase 1 clinical trial in patients with
heavily-pretreated advanced solid tumors, TPST-1120 as monotherapy
and in combination with the PD-1 inhibitor nivolumab demonstrated
tumor reduction (including RECIST responses) and biomarker
modulation. In a global randomized phase 1b/2 study of TPST-1120 in
combination with atezolizumab and bevacizumab in first-line
patients with advanced hepatocellular carcinoma (HCC), the
TPST-1120 arm showed clinical superiority across multiple study
endpoints when compared to atezolizumab and bevacizumab alone, the
standard of care. TPST-1120 is wholly-owned by Tempest.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
biotechnology company advancing a diverse portfolio of small
molecule product candidates containing tumor-targeted and/or
immune-mediated mechanisms with the potential to treat a wide range
of tumors. The company’s novel programs range from early research
to later-stage investigation in a randomized global study in
first-line cancer patients. Tempest is headquartered in Brisbane,
California. More information about Tempest can be found on the
company’s website at www.tempesttx.com.
Investor & Media Contacts
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
i If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Sep 2023 to Sep 2024